Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis; ...

Please provide your email address to receive an email when new articles are posted on . Perceptual learning significantly improved spectacle-corrected distance visual acuity. Patients assigned to ...

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

Please provide your email address to receive an email when new articles are posted on . Ophthalmologists can usually examine the cornea, lens and vitreous with the slit lamp to learn if there is ...

OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ACUITY ...

ZUG, Switzerland, January 6, 2025 – Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...